breast cancer - triple negative | ||
mBC-Triple negative (TNBC) - 2nd Line (L2) | mBC - TNBC - L2 - all population | |
poly ADP-ribose polymerase (PARP) inhibitor | ||
olaparib | OlympiAD | |
talazoparib | EMBRACA |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -